| Bioactivity | Imirestat (AL 1576) is an aldose reductase inhibitor, used for the treatment of diabetes. | ||||||||||||
| In Vivo | Imirestat (1 mg/kg) improves nerve conduction velocity but is without effect upon the resistance to hypoxic conduction blockade or the deficit in insulin-stimulated oubain-sensitive ATPase activity[1]. | ||||||||||||
| Name | Imirestat | ||||||||||||
| CAS | 89391-50-4 | ||||||||||||
| Formula | C15H8F2N2O2 | ||||||||||||
| Molar Mass | 286.23 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Carrington AL, et al. Aldose reductase inhibition with imirestat-effects on impulse conduction and insulin-stimulation of Na+/K(+)-adenosine triphosphatase activity in sciatic nerves of streptozotocin-diabetic rats. Diabetologia. 1991 Jun;34(6):397-401. |